STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.

Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.

Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.

Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.

Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of

Rhea-AI Summary
Amgen (NASDAQ:AMGN) will report its Q3 financial results on October 31, 2023, followed by a conference call with the investment community. The webcast will be available on Amgen's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
Amgen declares $2.13 per share dividend for Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
dividends
-
Rhea-AI Summary
Amgen announces positive results from Phase 3 trial of LUMAKRAS in patients with KRAS G12C-mutated colorectal cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Amgen announces positive results for tarlatamab in patients with advanced small cell lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary
Amgen to host webcasted call for investment community following presentation of new data from oncology portfolio
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
-
Rhea-AI Summary
Amgen presents new data at ESMO Congress 2023, highlighting potential of various therapies in tough-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
Rhea-AI Summary
Amgen completes acquisition of Horizon Therapeutics for $27.8 billion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary
deCODE Genetics scientists release findings from plasma proteomics study, demonstrating how it can contribute to understanding diseases. Associations found between diseases and specific proteins. Leveraging genetic factors can uncover molecular mechanisms of disease development. Data from 50,000 individuals analyzed using two platforms. Discrepancies between platforms affect biomarker discovery. Validation of individual assays necessary. deCODE is a global leader in genome analysis. Wholly-owned subsidiary of Amgen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
Rhea-AI Summary
Amgen launches Amgen Partners of Choice network to advance collaboration in oncology research and development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
Rhea-AI Summary
Scientists at deCODE genetics, a subsidiary of Amgen, publish a study on the complex effects of sequence variants on lipid levels and coronary artery disease. The study shows that carriers of a particular sequence variant are protected against the negative effects of alcohol consumption on coronary artery disease. Carriers of another sequence variant are more susceptible to increases in bad cholesterol upon consumption of oily fish. The study also demonstrates that homozygotes of the APOE2 allele have high levels of bad cholesterol but fewer particles carrying the cholesterol, conferring similar risk of developing coronary artery disease as non-carriers. Blood group secretor status influences cholesterol levels and cardiovascular disease risk among individuals not in the A1 blood group. These findings highlight the complex interaction between the genome and the environment in affecting health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none

FAQ

What is the current stock price of Amgen (AMGN)?

The current stock price of Amgen (AMGN) is $264.49 as of December 24, 2024.

What is the market cap of Amgen (AMGN)?

The market cap of Amgen (AMGN) is approximately 142.2B.

Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

142.17B
536.09M
0.21%
81.11%
1.82%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS